CMND
Clearmind Medicine Inc. (NASDAQ)
Healthcare — Biotechnology
Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, the company has a strategic collaboration with SciSparc Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem, Polyrizon Ltd., and NeuroThera Labs Inc. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.
Price History
Fundamentals
| Market Cap | $3.42M |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | $-175.92 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -114.61% |
| Debt/Equity | 0.75 |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 18.7 |
| Beta | -1.24 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $524.00 |
| 52-Week Low | $2.04 |
| 50-Day Avg | $4.29 |
| 200-Day Avg | $95.33 |
| Avg Volume | $2.24M |
| Volume | 176.4K |
Performance Analysis
NEUTRALCMND presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:03 UTC
Back to Screener Export Report